https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-12-22 / Integr Cancer Ther 2019 Jan-Dec;18:1534735418812691
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-12-22 / Integr Cancer Ther 2019 Jan-Dec;18:15347354188126912018-12-22 00:00:002018-12-22 00:00:00Modulated Electrohyperthermia in Integrative Cancer Treatment for Relapsed Malignant Glioblastoma and Astrocytoma: Retrospective Multicenter Controlled Study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-12-10 / Int J Oncol 2019 Feb;54(2):407-419
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-12-10 / Int J Oncol 2019 Feb;54(2):407-4192018-12-10 00:00:002021-11-15 20:14:26From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-12-05 / Blood Rev. 2019 03;34:67-83
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-12-05 / Blood Rev. 2019 03;34:67-832018-12-05 00:00:002018-12-05 00:00:00Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-12-05 / Acta Neuropathol Commun 2018 12;6(1):135
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-12-05 / Acta Neuropathol Commun 2018 12;6(1):1352018-12-05 00:00:002018-12-05 00:00:00Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-12-05 / Front Immunol 2018;9:2759
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-12-05 / Front Immunol 2018;9:27592018-12-05 00:00:002018-12-05 00:00:00Combination Strategies to Optimize Efficacy of Dendritic Cell-Based Immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-12-04 / Clin. Cancer Res. 2019 Mar;25(5):1494-1504
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-12-04 / Clin. Cancer Res. 2019 Mar;25(5):1494-15042018-12-04 00:00:002018-12-04 00:00:00Autologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with S-1 Plus Cisplatin in Patients with Advanced Gastric Cancer: A Prospective Study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-12-03 / Front Immunol 2018;9:2804
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-12-03 / Front Immunol 2018;9:28042018-12-03 00:00:002018-12-03 00:00:00Current State of Dendritic Cell-Based Immunotherapy: Opportunities for Antigen Loading of Different DC Subsets?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
IOZK
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
IOZK2018-12-01 18:15:082021-11-15 17:54:58International Journal of Oncology: „Von der Chemotherapie zur biologischen Therapie“, Prof. Dr. Volker Schirrmacher
